NextFin News - Apollo Global Management is nearing a deal to invest in vVardis, a Swiss dental technology company founded by sisters Haley and Goly Abivardi, in a transaction that values the startup at approximately $1 billion. According to Bloomberg, the private equity giant is in advanced talks to provide capital that would accelerate the global rollout of the firm’s drill-free cavity treatments. The deal, which has not yet been formally announced, marks a significant escalation in the valuation of a company that was raising funds at a much smaller scale just two years ago.
The Abivardi sisters, who previously built and sold the Swiss Smile dental chain, launched vVardis with a focus on "biomimetic" technology. Their flagship product, Curodont, claims to regenerate tooth enamel and treat early-stage cavities without the need for traditional drilling or filling. This shift toward minimally invasive dentistry has attracted substantial interest from healthcare-focused investors. OrbiMed, a prominent healthcare investment firm, previously led an $85 million funding round for the company. Matthew Rizzo, a general partner at OrbiMed, has historically maintained a bullish stance on the dental technology sector, arguing that the market is ripe for disruption by preventive care solutions. However, Rizzo’s optimistic outlook is specific to the high-growth potential of medical devices and may not reflect a broader consensus on the immediate profitability of the dental services market.
The $1 billion valuation represents a "unicorn" milestone for vVardis, yet it arrives at a time when the private equity industry is under increased scrutiny for its role in healthcare consolidation. While Apollo’s entry suggests a high degree of confidence in the scalability of vVardis’s technology, some industry analysts remain cautious. The dental market is notoriously fragmented, and the adoption of new clinical protocols often faces resistance from traditional practitioners. From the perspective of clinical adoption, the success of the investment hinges on whether vVardis can convince a critical mass of dentists to abandon lucrative traditional filling procedures in favor of its regenerative gel.
Apollo’s interest in vVardis aligns with a broader strategy under U.S. President Trump’s administration to encourage private capital flows into healthcare innovation and domestic manufacturing. The firm has been active in diversifying its portfolio, recently committing $1 billion to a retail joint venture with Realty Income and expanding its supplier diversity targets. By backing a high-tech dental firm, Apollo is positioning itself at the intersection of consumer wellness and medical technology, sectors that have shown resilience against inflationary pressures.
Despite the momentum, the deal’s finalization remains subject to market conditions and regulatory approvals. The high valuation multiple—typical for software-as-a-service but rare for dental product manufacturers—suggests that Apollo is betting on vVardis becoming a platform for a wider range of oral health products. If the technology fails to achieve the projected 10% penetration rate in the U.S. market, or if insurance reimbursement remains limited for "preventive" treatments, the $1 billion price tag could prove difficult to justify in a subsequent exit or public offering.
Explore more exclusive insights at nextfin.ai.
